Loading...
XNASEVOK
Market cap7mUSD
Dec 27, Last price  
4.86USD
1D
-0.61%
1Q
1.04%
Jan 2017
-79.95%
IPO
-96.54%
Name

Evoke Pharma Inc

Chart & Performance

D1W1MN
XNAS:EVOK chart
P/E
—
P/S
1.39
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-27.42%
Rev. gr., 5y
0.00%
Revenues
5m
+106.51%
00000000023,0201,618,0762,508,6455,180,630
Net income
-8m
L-4.53%
-2,401,244-2,017,528-2,836,465-13,247,681-12,121,463-10,748,531-12,229,512-7,566,080-7,096,857-13,261,993-9,029,387-8,162,123-7,792,295
CFO
-5m
L-24.42%
-2,893,108-1,749,863-3,040,270-11,501,072-10,495,838-8,707,742-8,716,905-6,978,560-5,762,093-6,630,007-12,352,944-6,595,987-4,984,977
Earnings
Mar 12, 2025

Profile

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
URL
https://evokepharma.com/
IPO date
Sep 25, 2013
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,181
106.51%
2,509
55.04%
1,618
6,929.00%
Cost of revenue
384
671
919
Unusual Expense (Income)
NOPBT
4,797
1,837
699
NOPBT Margin
92.59%
73.25%
43.23%
Operating Taxes
(62)
491
Tax Rate
70.26%
NOPAT
4,797
1,899
208
Net income
(7,792)
-4.53%
(8,162)
-9.60%
(9,029)
-31.92%
Dividends
Dividend yield
Proceeds from repurchase of equity
(119)
7,444
13,429
BB yield
40.77%
-88.36%
-75.86%
Debt
Debt current
5,000
129
12
Long-term debt
5,000
5,129
5,012
Deferred revenue
Other long-term liabilities
1,612
1,112
612
Net debt
5,261
(4,586)
(4,120)
Cash flow
Cash from operating activities
(4,985)
(6,596)
(12,353)
CAPEX
(3)
Cash from investing activities
Cash from financing activities
(119)
7,295
13,429
FCF
874
1,783
337
Balance
Cash
4,739
9,844
9,145
Long term investments
Excess cash
4,480
9,718
9,064
Stockholders' equity
(123,439)
(115,647)
(107,420)
Invested Capital
132,472
125,973
116,600
ROIC
3.71%
1.57%
0.19%
ROCE
53.10%
17.79%
7.62%
EV
Common stock shares outstanding
279
3,144
2,682
Price
1.05
-60.81%
2.68
-59.39%
6.60
-78.68%
Market cap
293
-96.53%
8,425
-52.41%
17,702
-73.08%
EV
5,553
3,839
13,582
EBITDA
4,797
1,837
699
EV/EBITDA
1.16
2.09
19.42
Interest
500
500
500
Interest/NOPBT
10.42%
27.21%
71.49%